Download PDF
Der Klinikarzt 2017; 46(11): 536-543
DOI: 10.1055/s-0043-121771
Schwerpunkt
© Georg Thieme Verlag Stuttgart · New York

Personalisierte Tumortherapie bei metastasierten gastrointestinalen Tumoren

Aktueller Stand und Einordnung in den klinischen Kontext
Hanna Bartholomäus
,
Thomas J. Ettrich
,
Thomas Seufferlein
Further Information

Publication History

Publication Date:
15 November 2017 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Personalisierte Therapiestrategien haben sich in den letzten Jahren auch in der gastrointestinalen Onkologie etabliert. Personalisierte Therapiestrategien umfassen Substanzen, die gezielt am Tumor angreifen, sog. „targeted therapies“. Zunehmende Bedeutung als Targets gewinnen das Microenvironment des Tumors und das Immunsystem. Parallel zu den neuen Substanzen werden Biomarker identifiziert, die den Einsatz einer bestimmten Substanz sinnvoll erscheinen lassen oder ausschließen. Dies ist nicht nur vorteilhaft für Patienten, die so Therapien mit hoher Aussicht auf Wirksamkeit erhalten, sondern auch für das Gesundheitswesen, dem Kosten für nicht wirksame Therapien erspart bleiben. Diese Übersicht soll den aktuellen Stand von personalisierten Therapiestrategien bei kolorektalen, Pankreas- und Magenkarzinomen darstellen und in den klinischen Kontext einordnen.

 

  • Literatur

  • 1 Guinney J, Dienstmann R, Wang X. et al. The consencus molecular subtypes of colorectal cancer. Nat Med 2015; 21: 1350-1356
    CrossrefPubMedGoogle Scholar
  • 2 Graham DM, Coyle VM, Kennedy RD. et al. Molecular subtypes and personalized therapy in metastatic colorectal cancer. Curr Colorectal Cancer Rep 2016; 12: 141-150
    CrossrefPubMedGoogle Scholar
  • 3 Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014; 513: 202-209
    CrossrefPubMedGoogle Scholar
  • 4 Bailey P, Chang DK, Nones K. et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 2016; 531: 47-52
    CrossrefPubMedGoogle Scholar
  • 5 Heinemann V, von Weikersthal LF, Decker T. et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 2014; 15: 1065-1075
    CrossrefPubMedGoogle Scholar
  • 6 Wilke H, Muro K, Van Cutsem E. et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet 2014; Lancet Oncol 15: 1224-1235
    CrossrefPubMedGoogle Scholar
  • 7 Vidal J, Muinelo L, Dalmases A. et al. Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients. Ann Oncol 2017; 28: 1325-1332
    CrossrefPubMedGoogle Scholar
  • 8 Di Nicolantonio F, Martini M, Molinari F. et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008; 26: 5705-5712
    CrossrefPubMedGoogle Scholar
  • 9 Jones JC, Renfro LA, Al-Shamsi HO. et al. Non-V600 BRAF mutations define a clinically distinct molecular subtype of metastatic colorectal cancer. J Clin Oncol 2017; 35: 2624-2630
    CrossrefPubMedGoogle Scholar
  • 10 Cremolini C, Loupakis F, Antoniotti C. et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol 2015; 16: 1306-1315
    CrossrefPubMedGoogle Scholar
  • 11 Sortore-Bianchi A, Trusolino L, Martino C. et al. Dual-targeted therapy with trastuzumab and lapatinib in treatmet-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol 2016; 17: 738-746
    CrossrefPubMedGoogle Scholar
  • 12 Douillard JY, Oliner KS, Siena S. et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013; 369: 1023-1034
    CrossrefPubMedGoogle Scholar
  • 13 Schwartzberg LS, Rivera F, Karthaus M. et al. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol 2014; 32: 2240-2247
    CrossrefPubMedGoogle Scholar
  • 14 Stinzing S, Miller-Phillips L, Modest DP. et al. FIRE-3 Investigators. Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study. Eur J Cancer 2017; 79: 50-60
    CrossrefPubMedGoogle Scholar
  • 15 Lenz H, Niedzwiecki D, Innocenti F. et al. CALGB/SWOG 80405: PHASE III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with expanded ras analyses untreated metastatic adenocarcinoma of the colon or rectum (mCRC). Ann Onc 2014; 5: 1-41
    PubMedGoogle Scholar
  • 16 Van Cutsem E, Lenz HJ, Köhne CH. et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol 2015; 33: 692-700
    CrossrefPubMedGoogle Scholar
  • 17 Holch JW, Ricard I, Stintzing S. et al. The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials. Eur J Cancer 2017; 70: 87-98
    CrossrefPubMedGoogle Scholar
  • 18 Misale S, Yaeger R, Hobor S. et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012; 486: 532-536
    CrossrefPubMedGoogle Scholar
  • 19 Corcoran RB, Ebi H, Turke AB. et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov 2012; 2: 227-235
    CrossrefPubMedGoogle Scholar
  • 20 Kopetz S, Desai J, Chan E. et al. Phase II Pilot Study of Vemurafenib in patients with metastatic BRAF-mutated colorectal cancer. J Clin Oncol 2015; 33: 4032-4038
    CrossrefPubMedGoogle Scholar
  • 21 Bang YJ, Van Cutsem E, Feyereislova A. et al. ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687-697
    CrossrefPubMedGoogle Scholar
  • 22 Tabernero J, Hoff PM, Shen L. Pertuzumab (P) + trastuzumab (H) + chemotherapy (CT) for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (mGC/GEJC): final analysis of a phase III study (JACOB). Presented at: European Society for Medical Oncology (ESMO) 2017 Congress; September 8–12 2017. Madrid, Spain:
    CrossrefGoogle Scholar
  • 23 Saltz LB, Clarke S, Diaz-Rubio E. et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-2019
    CrossrefPubMedGoogle Scholar
  • 24 Giantonio BJ, Catalano PJ, Meropol NJ. et al. Eastern Cooperative Oncology Group Study E3200. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25: 1539-1544
    CrossrefPubMedGoogle Scholar
  • 25 Bennouna J, Sastre J, Arnold D. et al. ML18147 Study Investigators. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2013; 14: 29-37
    CrossrefPubMedGoogle Scholar
  • 26 Tabernero J, Van Cutsem E, Lakomy R. et al. Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. Eur J Cancer 2014; 50: 320-331
    CrossrefPubMedGoogle Scholar
  • 27 Kabbinavar F, Hurwitz HI, Fehrenbacher L. et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 60-65
    CrossrefPubMedGoogle Scholar
  • 28 Cunningham D, Lang I, Marcuello E. et al. AVES study investigators. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol 2013; 14: 1077-1085
    CrossrefPubMedGoogle Scholar
  • 29 Simkens LH, van Tinteren H, May A. et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet 2015; 385: 1843-1852
    CrossrefPubMedGoogle Scholar
  • 30 Arnold D, Graeven U, Lerchenmuller CA. et al. Maintenance strategy with fluoropyrimidines (FP) plus Bevacizumab (Bev), Bev alone, or no treatment, following a standard combination of FP, oxaliplatin (Ox), and Bev as first-line treatment for patients with metastatic colorectal cancer (mCRC): A phase III non-inferiority trial (AIO KRK 0207). J Clin Oncol 2014; 32 5 s (suppl; abstr 3503)
    PubMedGoogle Scholar
  • 31 Vogelstein B, Fearon ER, Hamilton SR. et al. Genetic alterations during colorectal tumor development. N Engl J Med 1988; 319: 525-532
    CrossrefPubMedGoogle Scholar
  • 32 Fuchs CS, Tomasek J, Yong CJ. et al. REGARD Trial Investigators. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014; 383: 31-39
    CrossrefPubMedGoogle Scholar
  • 33 Özdemir BC, Pentcheva-Hoang T, Carstens JL. et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 2014; 25: 719-734
    CrossrefPubMedGoogle Scholar
  • 34 Rhim AD, Oberstein PE, Thomas DH. et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell 2014; 25: 735-747
    CrossrefPubMedGoogle Scholar
  • 35 Hingorani SR, Harris WP, Hendifar AE. et al. High response rate an PFS with PEGPH20 added to nab-paclitaxel/gemcitabine in stage IV previously untreated pancreatic cancer patients with high-HA tumors: Interim results of a randomized phase II study. J Clin Oncol 2015; 33 (suppl; abstr 4006)
    PubMedGoogle Scholar
  • 36 Le DT, Uram JN, Wang H. et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med 2015; 372: 2509-2510
    CrossrefPubMedGoogle Scholar
  • 37 Fuchs CS, Doi T, Jang RWJ. et al. KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer. J Clin Oncol 2017; 35 (suppl; abstr 4003)
    PubMedGoogle Scholar
  • 38 Janjigian YY, Ott PA, Calvo E. et al. Nivolumab ± ipilimumab in pts with advanced (adv)/metastatic chemotherapy-refractory (CTx-R) gastric (G), esophageal (E), or gastroesophageal junction (GEJ) cancer: CheckMate 032 study. J Clin Oncol 2017; 35 (suppl; abstr 4014)
    PubMedGoogle Scholar
  • 39 Boku N, Kang YK, Sato T. et al. A phase 3 study of nivolumab (nivo) in previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: Updated results and subset analysis by PD-L1 expression (ATTRACTION-02). Ann Oncol 2017; 28 (suppl_5; Abstr 617O)
    PubMedGoogle Scholar